{"id":38990,"title":"Google DeepMind Boss Announces AI Drug Trials Set for late year","publisher":"Stockmark.IT","author":"Stockmark.IT Website","published":"2025-01-23T04:25:10+00:00","modified":"2025-01-22T18:29:34+00:00","canonical_url":"https://stockmark.it/google-deepmind-boss-announces-ai-drug-trials-set-for-late-year/","markdown_url":"https://stockmark.it/google-deepmind-boss-announces-ai-drug-trials-set-for-late-year.md","json_url":"https://stockmark.it/google-deepmind-boss-announces-ai-drug-trials-set-for-late-year.json","category":"Artificial intelligence","categories":["Artificial intelligence","Drug Research","Google","Pharmaceutical"],"featured_image":"https://i0.wp.com/stockmark.it/wp-content/uploads/2023/01/google-st-1.jpg?fit=800%2C400&quality=89&ssl=1","format":"news","language":"en-GB","content":"In a groundbreaking announcement at the World Economic Forum in Davos, Sir Demis Hassabis revealed that Isomorphic Labs, the Alphabet-owned drug discovery startup, will commence trials of its first AI-designed drug by year-end.\n\nThe Nobel Prize-winning chief executive outlined ambitious plans to revolutionise drug development through artificial intelligence, potentially reducing the traditional five to ten-year discovery timeline by a factor of ten. The company’s focus spans major therapeutic areas including oncology, cardiovascular disease, and neurodegeneration.\n\nIsomorphic Labs, which emerged from Google’s AI research division in 2021, has already secured partnerships with pharmaceutical giants Eli Lilly and Novartis. These collaborations aim to streamline the costly drug development process, marking a significant shift in how new medicines are discovered.\n\nBeyond pharmaceutical innovations, Hassabis shared insights about Google’s AI developments, including Project Astra, a consumer-focused AI assistant scheduled for release later this year. His vision extends to a near future where billions of AI agents conduct automated negotiations across a reimagined internet landscape.\n\nThe DeepMind chief also addressed concerns about artificial general intelligence (AGI), estimating its arrival within five to ten years. He emphasised the need for careful stewardship of AI development, acknowledging that while the technology cannot be contained, its implementation must prioritise safety and ethical considerations.\n\nThe convergence of AI and healthcare represents a watershed moment in medical science, with Isomorphic Labs positioning itself at the forefront of this technological revolution. As these trials commence, the healthcare sector watches closely to see if AI can deliver on its promise to transform drug discovery."}